
News|Articles|February 3, 2025
Data-Driven Insights can Optimize Clinical Trial Site Selection
Author(s)PurpleLab
Clinical trials are crucial for drug development but often face delays due to poor site selection, which can lead to protocol violations, poor data quality, and increased costs. Ninety percent of clinical trials fail to meet their timelines, and issues like inadequate staffing and patient recruitment are significant challenges. Traditional site selection methods are inefficient, and the COVID-19 pandemic has further complicated the process. Data-driven insights can optimize site selection by evaluating current data on patient populations, investigators, and site capabilities.
Trending on Applied Clinical Trials Online
1
The Evolution of Preclinical CRO Strategic Partnerships: From Transactional Services to Value-Driven Ecosystems in 2026
2
The Execution Gap: Why Clinical Trial Infrastructure Has to Be Built Before AI Can Deliver
3
What the Epilepsy Community Has Taught Us About Trial Feasibility
4
Predictive Clinical Development: Accelerating Success From Design to Delivery
5